Page 137 - 2019_01-Haematologica-web

Gemtuzumab in pediatric acute myeloid leukemia
et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunoru- bicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607.
8. Gorman MF, Ji L, Ko RH, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010;55(3):421-429.
9. Webb DK. Management of relapsed acute myeloid leukaemia. Br J Haematol. 1999;106(4):851-859.
10. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007;109(1):157-163.
11. Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017;18(3):17.
12. Moore AS, Kearns PR, Knapper S, Pearson AD, Zwaan CM. Novel therapies for chil- dren with acute myeloid leukaemia. Leukemia. 2013;27(7):1451-1460.
13. Tasian SK, Pollard JA, Aplenc R. Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol. 2014;4:55.
14. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of mono- clonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53(14):3336-3342.
15. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti- CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678-3684.
16. Maniecki MB, Hasle H, Bendix K, Moller HJ. Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to spe- cific targeting of hepatocytes? Leuk Res. 2011;35(6):e84-e86.
17. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101(10):3868-3871.
18. Zwaan CM, Reinhardt D, Zimmerman M, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148(5):768-776.
19. Brethon B, Yakouben K, Oudot C, et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol. 2008;143(4):541-547.
20. ClinicalTrials.gov. Expanded Access/ Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML). 2017 [cited Jan 2018]; Available from: https://clinicaltrials.gov.
21. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four con- secutive AML-BFM trials. Leukemia. 2005;19(12):2030-2042.
22. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of gran- ulocyte colony-stimulating factor in chil- dren and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499-4506.
23. Creutzig U, Zimmermann M, Dworzak M, et al. Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity. Blood. 2010;116(21):181.
24. Creutzig U, Zimmermann M, Dworzak MN, et al. The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. Haematologica. 2014;99(9):1472- 1478.
25.
26.
27.
28.
29.
30.
31.
32.
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010 [cited August 2016]; Available from: http://ctep.cancer.gov.
Davila J, Slotkin E, Renaud T. Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments. Paediatr Drugs. 2014;16(2):151-168.
Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005; 106(4):1183-1188.
Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2008;26(14):2390-3295.
Brethon B, Auvrignon A, Galambrun C, et al. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal anti- body, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. BMC Cancer. 2006;6:172.
Roman E, Cooney E, Harrison L, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res. 2005;11(19):7164-7170. Satwani P, Bhatia M, Garvin JH, Jr., et al. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative con- ditioning (MAC) regimen. Biol Blood Marrow Transplant. 2012;18(2):324-329. Parigger J, Zwaan CM, Reinhardt D, Kaspers GJ. Dose-related efficacy and toxi- city of gemtuzumab ozogamicin in pedi- atric acute myeloid leukemia. Expert Rev Anticancer Ther. 2016;16(2):137-146.
haematologica | 2019; 104(1)
127